Voya Investment Management LLC Trims Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Voya Investment Management LLC decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 48.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,007 shares of the biopharmaceutical company's stock after selling 30,733 shares during the quarter. Voya Investment Management LLC owned approximately 0.06% of Agios Pharmaceuticals worth $1,085,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AGIO. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $33,000. Wingate Wealth Advisors Inc. bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $53,000. Sterling Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 1,587 shares during the period. KBC Group NV increased its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares during the period.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright started coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Finally, Scotiabank reduced their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO traded down $0.72 on Friday, hitting $27.32. The stock had a trading volume of 303,182 shares, compared to its average volume of 696,244. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The firm's fifty day simple moving average is $29.23 and its two-hundred day simple moving average is $37.27. The stock has a market cap of $1.58 billion, a P/E ratio of 2.41 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.